Cytek Debt To Equity from 2010 to 2026
| CTKB Stock | USD 4.23 -0.13 -2.98% |
Debt To Equity | First Reported 2010-12-31 | Previous Quarter 0.09663515 | Current Value 0.1 | Quarterly Volatility 0.1160008 |
Use the financial statements timeline for Cytek Biosciences to frame performance drivers and balance sheet structure. Track Tax Provision of 38.5 M, Net Interest Income of 2.9 M or Interest Income of 4 M and ratios such as Price To Sales Ratio of 3.04, Dividend Yield of 0.0 or PTB Ratio of 1.98 to align performance context with Cytek Biosciences Valuation and Volatility.
Cytek | Debt To Equity | Build AI portfolio with Cytek Stock |
Analyzing Cytek Biosciences's Debt To Equity over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Debt To Equity has evolved provides context for assessing Cytek Biosciences's current valuation and future prospects.
Latest Cytek Biosciences' Debt To Equity Growth Pattern
Below is the plot of the Debt To Equity of Cytek Biosciences over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Cytek Biosciences' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytek Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.04 % | 10 Years Trend |
|
Debt To Equity |
| Timeline |
Cytek Debt To Equity Regression Statistics
| Arithmetic Mean | -0.09 | |
| Coefficient Of Variation | -127.91 | |
| Mean Deviation | 0.11 | |
| Median | -0.17 | |
| Standard Deviation | 0.12 | |
| Sample Variance | 0.01 | |
| Range | 0.2729 | |
| R-Value | 0.84 | |
| Mean Square Error | 0.0041 | |
| R-Squared | 0.71 | |
| Significance | 0.00002 | |
| Slope | 0.02 | |
| Total Sum of Squares | 0.22 |
Cytek Debt To Equity History
How Much Is Cytek Biosciences Worth?
Cytek Biosciences is a small-cap equity in Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care categories. Operating leverage influences fair value range. We review the company from a portfolio-construction standpoint emphasizing diversification and stability.
Methodology
Unless otherwise specified, financial data for Cytek Biosciences is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Cytek (USA Stocks:CTKB) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions Valuation estimates and intrinsic-value models use inputs from public financial disclosures and may not represent market consensus.
Assumptions
Inputs are aggregated from public filings and market reference sources and public institutions such as U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Food & Drug Administration (FDA). Certain values may not reflect real-time changes. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.Analyst Sources
Cytek Biosciences is covered by 5 analysts. 2 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Oppenheimer & Co., Jefferies, Stifel, BMO Capital Markets, HSBC Global Research, among others. Updates may occur throughout the day.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.More Resources for Cytek Stock Analysis
Understanding Cytek Biosciences typically begins with financial statements and long-term trend review. Ratios and trend metrics help frame Cytek Biosciences' operating context. Below are reports that help frame Cytek Biosciences Stock in context:Use Cytek Biosciences Correlation to compare Cytek Biosciences against competitors. The view adds relative comparison context. Discover how to invest in Cytek Stock by reading our How to Buy Cytek Stock guide.Analysis related to Cytek Biosciences should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Portfolio Holdings module to check your current holdings and cash position to determine if your portfolio needs rebalancing.
Quarterly Earnings Growth 0.735 | Earnings Share -0.52 | Revenue Per Share | Quarterly Revenue Growth 0.081 | Return On Assets |
Cytek Biosciences market price can diverge from book value, the accounting figure shown on Cytek balance sheet. The intrinsic value concept focuses on underlying worth, which can diverge from market price and book value. Market price responds to sentiment, liquidity, and macro shifts, so gaps can appear. Valuation work aligns these measures into a single context.
It is useful to distinguish Cytek Biosciences' value from its trading price, which are computed with different methods. Context can include financial performance, operating efficiency, market trends, and peer comparisons. Market price reflects the current exchange level formed by active bids and offers.